Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Reiterates Outperform on Viracta Therapeutics, Maintains $8 Price Target

RBC Capital analyst Gregory Renza reiterates Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $8 price target.

RBC Capital analyst Gregory Renza reiterates Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $8 price target.

Total
0
Shares